108 related articles for article (PubMed ID: 34214366)
21. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
22. IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling.
Ahmed S; Mohamed HT; El-Husseiny N; El Mahdy MM; Safwat G; Diab AA; El-Sherif AA; El-Shinawi M; Mohamed MM
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):118995. PubMed ID: 33667527
[TBL] [Abstract][Full Text] [Related]
23. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
Kim JS; Kim HA; Seong MK; Seol H; Oh JS; Kim EK; Chang JW; Hwang SG; Noh WC
Oncotarget; 2016 Feb; 7(6):7055-65. PubMed ID: 26755645
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
Gupta P; Srivastava SK
BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
[TBL] [Abstract][Full Text] [Related]
25. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
26. Ras-induced resistance to lapatinib is overcome by MEK inhibition.
Zoppoli G; Moran E; Soncini D; Cea M; Garuti A; Rocco I; Cirmena G; Grillo V; Bagnasco L; Icardi G; Ansaldi F; Parodi S; Patrone F; Ballestrero A; Nencioni A
Curr Cancer Drug Targets; 2010 Mar; 10(2):168-75. PubMed ID: 20088787
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
28. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Gayle SS; Castellino RC; Buss MC; Nahta R
Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
[TBL] [Abstract][Full Text] [Related]
29. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21.
Prabaharan CB; Yang AB; Chidambaram D; Rajamanickam K; Napper S; Sakharkar MK
Invest New Drugs; 2020 Aug; 38(4):909-921. PubMed ID: 31375978
[TBL] [Abstract][Full Text] [Related]
31. Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells.
Seo HS; Jo JK; Ku JM; Choi HS; Choi YK; Woo JK; Kim HI; Kang SY; Lee KM; Nam KW; Park N; Jang BH; Shin YC; Ko SG
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26500281
[TBL] [Abstract][Full Text] [Related]
32. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
33. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
Nahta R; Yuan LX; Du Y; Esteva FJ
Mol Cancer Ther; 2007 Feb; 6(2):667-74. PubMed ID: 17308062
[TBL] [Abstract][Full Text] [Related]
34. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.
Shang AQ; Wu J; Bi F; Zhang YJ; Xu LR; Li LL; Chen FF; Wang WW; Zhu JJ; Liu YY
Cancer Biol Ther; 2017 May; 18(5):314-322. PubMed ID: 28448787
[TBL] [Abstract][Full Text] [Related]
35. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
[TBL] [Abstract][Full Text] [Related]
36. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.
Weigelt B; Lo AT; Park CC; Gray JW; Bissell MJ
Breast Cancer Res Treat; 2010 Jul; 122(1):35-43. PubMed ID: 19701706
[TBL] [Abstract][Full Text] [Related]
37. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
Chang Y; Park KH; Lee JE; Han KC
Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
[TBL] [Abstract][Full Text] [Related]
38. Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells.
Seo HS; Ku JM; Choi HS; Choi YK; Woo JK; Kim M; Kim I; Na CH; Hur H; Jang BH; Shin YC; Ko SG
Oncol Rep; 2016 Jul; 36(1):31-42. PubMed ID: 27175602
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Sethunath V; Hu H; De Angelis C; Veeraraghavan J; Qin L; Wang N; Simon LM; Wang T; Fu X; Nardone A; Pereira R; Nanda S; Griffith OL; Tsimelzon A; Shaw C; Chamness GC; Reis-Filho JS; Weigelt B; Heiser LM; Hilsenbeck SG; Huang S; Rimawi MF; Gray JW; Osborne CK; Schiff R
Mol Cancer Res; 2019 Nov; 17(11):2318-2330. PubMed ID: 31420371
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
